^
Association details:
| Biomarker: | NRG1 fusion |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Bizengri (zenocutuzumab-zbco) (HER2 inhibitor, HER3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions.
Published date:
05/19/2021
Excerpt:
Zeno induces rapid and major radiologic tumor regression and biomarker responses in heavily-pretreated metastatic KRAS wild-type NRG1+ pancreas cancer, with minimal toxicity.
DOI:
10.1200/JCO.2021.39.15_suppl.3003
Trial ID:
